- **DSA Growth**: 12% revenue rise, 27% YoY awards increase, 1.16:1 book-to-bill ratio highlight DSA strength.
- **RMS Challenges**: 5.4% revenue decline, 25% NHP volume drop weigh on margins; site optimization costs persist.
- **Financial Health**: Net loss $28.4M, adjusted EBITDA $1.8M; cash $12.7M, debt $405.8M.
- **Strategic Moves**: Debt refinancing in progress; NAMs collaborations to drive innovation and reduce animal use.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue $120.9M (Q1 2026) vs $119.9M (Q1 2025), driven by 12% DSA growth (to $48M) and 13% RMS services growth, offset by 5.4% RMS revenue decline.
- **DSA Momentum**: Discovery & translational sciences (DTS) up 26%, safety assessment up 7%. Q1 DSA awards $53.6M (+27% YoY), trailing 12M awards +34%. Book-to-bill 1.16:1 (Q1) and 1.08:1 (12M).
- **RMS Challenges**: NHP sales down 25% YoY, RMS operating loss $16.3M (+$2.4M YoY). NHP services revenue up 13%.
- **Strategic Initiatives**: Site optimization closures of 2 leased facilities, $5.2M Q1 CapEx (4.3% of revenue). Engaged Perella Weinberg for debt refinancing; received covenant waiver.
- **NAMs Innovation**: Collaborations for machine learning tools and human tissue access to enhance human-relevant models.

**【CFO Financial Commentary】**
- **Profitability**: Consolidated net loss $28.4M (-$0.83 EPS) vs $27.6M (-$1.02 EPS). Adjusted EBITDA $1.8M (1.5% of revenue) vs $2.6M (2.2%).
- **Margins**: DSA operating income $8.2M (6.8% of revenue) vs $7.1M (5.9%). RMS operating income $7.2M (5.9%) vs $9.4M (7.9%).
- **Liquidity**: Cash $12.7M (down from $21.7M). Debt $405.8M, including $118.2M convertible notes.
- **Cash Flow**: Operating cash outflow $5.4M vs $4.5M. Capital expenditures $5.2M (4.3% of revenue).

**【Q&A Highlights】**
- **Profitability Drivers**: Lower NHP volume (-25% YoY) offset DSA margin gains. Pricing stabilization expected to improve margins in H2 2026.
- **Seasonality**: Q1 typically weaker due to university closures; Q2 starts strong with January awards (+27% YoY).
- **RMS Leverage**: Site optimization costs will reduce sequentially, but NHP volume recovery needed for margin improvement.
- **NAMs Impact**: Collaborations with machine learning tools and human tissue access to accelerate drug discovery timelines.
- **NHP Outlook**: Full-year 2026 NHP revenue expected flat vs 2025, with services growth offsetting lower sales volume.

Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript

- **Revenue Growth**: Q4 2025, DSA segment drives 5.9% YoY increase.
- **DSA Strength**: Awards up 61% YoY, with improving margins.
- **RMS Efficiency**: 13 facilities closed, reducing costs by $6M-$7M annually.
- **Cybersecurity Impact**: Q4 results reflect one-time recovery costs.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2025 total revenue of $138.1M, up 5.9% YoY, driven by DSA segment (+15.7% YoY to $51.6M). FY2025 revenue reached $513M, +4.5% YoY.
- **DSA Momentum**: Q4 DSA awards rose 61% YoY to $54.2M, with a book-to-bill ratio of 1.08:1. Backlog conversion rate hit 37.4%, highest in 3 years.
- **RMS Efficiency**: RMS revenue up 4.7% YoY, with 13 facilities closed since 2023, reducing costs by $6M-$7M annually.
- **Cybersecurity Impact**: Q4 results reflect costs from August incident, including third-party recovery efforts.

**【CFO Financial Commentary】
- **Profitability**: GAAP net loss of $8.6M, narrower than Q4 2024 loss of $18.9M. Adjusted EBITDA up 122% YoY.
- **Cash Flow**: Q4 cash from operations was $14.3M, boosting liquidity to $21.7M.

**【Q&A Highlights】**
- **Headwinds Quantified**: Cybersecurity costs included overtime and third-party expenses, though intangible impacts remain.
- **Q4 2025 Trends**: DSA awards up 37% YoY, but RMS faces seasonal slowdowns.
- **FDA Guidance**: Minimal exposure to FDA NAM impact, with NHP sales unaffected.


Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: Q3 2025 revenue up 23.5% YoY to $130.7M, driven by 34% RMS growth and 9% DSA expansion. Discovery services awards jumped 31.3% YoY.
- **Profitability Recovery**: EBITDA of $11.6M (8.9% margin), vs. $0.1M in Q3 2024. DSA margins improved 4.6% QoQ, though still lagging prior year.
- **Legal Closure**: SEC investigation resolved without enforcement; $10M legal accrual fully recoverable via insurance.
- **Operational Efficiency**: RMS margins at 12.9%, highest since Q1 2024. $6M-$7M annual savings target from $6.5M capital investments.
- **Customer Focus**: 60%-70% of customers use multiple sites; on-time delivery metrics improved, with emphasis on seamless multi-site service.

**【CEO Opening Remarks】**
- **Revenue Growth**: Q3 2025 revenue of $130.7M, up 23.5% YoY, driven by RMS (+34.1%) and DSA (+8.9%) segments. Net DSA awards increased 25% YoY, with Discovery services up 31.3%.
- **Margin Improvement**: EBITDA of $11.6M (8.9% of revenue), up from $0.1M in Q3 2024. DSA operating margins improved 4.6% QoQ, though still 0.8% below Q3 2024 levels.
- **Legal Resolution**: SEC investigation concluded without enforcement action; $10M legal accrual recorded, with full recovery expected via insurance.
- **Site Optimization**: RMS operating margins at 12.9%, highest since Q1 2024. $6M-$7M annual savings target from $6.5M capital investments, with 2 facility sales planned by Q4 2025.
- **Customer Satisfaction**: On-time delivery metrics improved, with 60%-70% of customers using multiple sites. Focus on seamless multi-site service experience.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: DSA ($48.2M, +9% YoY) driven by biotherapeutics and medical devices; RMS ($82.5M, +34% YoY) due to higher NHP volumes and prices.
- **Profitability**: Consolidated net loss of $17.6M (-$0.51 EPS) vs. $26.1M loss (-$1 EPS) in Q3 2024. Adjusted EBITDA of $11.6M, highest since Q4 2023.
- **Cash Flow**: $6.2M cash on hand vs. $21.4M in Q3 2024. Capital expenditures of $4M (3.1% of revenue), with annual spend expected below 4%.
- **Debt Management**: Total debt $396.5M, including $114.8M convertible notes. Focus on strategic balance sheet review and third-party advisory engagement.

**【Q&A Highlights】**
- **Cancellations Trend**: Q3 cancellations 31% higher YoY, but trailing 12-month rate up only 2%. CEO expects elevated cancellations to persist, requiring higher gross bookings.
- **Site Optimization Next Steps**: Shift to fine-tuning existing facilities vs. new construction. Dallas expansion and process improvements to drive capacity.
- **NHP Imports**: Cambodia imports remain possible, but no plans to resume; U.S. NHP supply stable, pricing unchanged.
- **Customer Satisfaction**: On-time delivery metrics significantly improved, with focus on multi-site coordination and root-cause analysis.
- **Cash Flow Outlook**: Higher NHP inventory to support customer demand, with potential to convert excess inventory to cash if needed.

Inotiv, Inc. (NOTV) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 4.4% YoY to $124.3M, driven by 9.1% RMS segment growth.
- **Margin Expansion**: RMS operating margins at 12.5%, with $6-7M annual savings from $6.5M site optimization project.
- **FDA Alignment**: NAMs adoption gradual; computational tox and ex vivo assays seeing incremental growth.
- **DSA Recovery**: Book-to-bill ratio 1.01:1, new orders up 27% YoY; expect margin improvement in H2 2025.
- **Tariff Impact**: 10% tariffs on NHP imports manageable; no material demand change yet.

**【CEO Opening Remarks】**
- Q2 2025 revenue: $124.3M (4.4% YoY growth), driven by RMS segment (+9.1%) due to higher NHP volumes.
- RMS operating margins improved to their strongest since Q1 2024; expect further margin expansion with $6.5M site optimization project (completed by Q1 2026, saving $6-7M annually).
- DSA segment revenue down 3% YoY due to lower general toxicology services, but book-to-bill ratio at 1.01:1 and new orders up 27% YoY.
- FDA's focus on NAMs (e.g., computational tox, ex vivo assays) aligns with Inotiv's existing capabilities; expect gradual adoption but no immediate replacement of animal models.
- Tariffs on NHP imports may impact costs, but no material demand change seen yet.

**【CFO Financial Highlights】**
- Adjusted EBITDA: $8M (6.4% of revenue) vs. $3.1M (2.6%) in Q2 2024.
- DSA non-GAAP operating income: $5M (4% of revenue) vs. $8.2M (6.9%) in Q2 2024.
- RMS non-GAAP operating income: $15.6M (12.5% of revenue) vs. $8.2M (6.9%) in Q2 2024.
- Net loss: $14.9M (-$0.44 EPS) vs. $48.1M (-$1.86 EPS) in Q2 2024.
- Cash: $19.3M; total debt: $399.5M.

**【Q&A Key Takeaways】**
- **FDA/NAMs**: Clients beginning to inquire about NAMs, but adoption slow; computational tox and proteomics services seeing incremental growth.
- **RMS Optimization**: Accelerated timeline for $6.5M project (completion by Q1 2026) to save $6-7M annually; focuses on reducing repair/maintenance costs and improving client service.
- **DSA Margins**: Expect sequential improvement in H2 2025 as higher-cost NHPs exit pipeline and discovery services leverage new capacity.
- **Tariffs**: 10% tariffs on NHP imports currently manageable; no clarity on higher tariffs' impact yet.
- **Investor Day**: Scheduled for May 29 to discuss strategic initiatives and client value proposition.

Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript

- **Revenue Volatility Mitigation**: $27.5M equity raise and NHP pre-sales to stabilize RMS (-15.1% YoY). 
- **Cost Efficiency**: $5M RMS consolidation to save $4-5M annually by 2026.
- **Margin Recovery**: NHP margins to improve Q2+ as high-cost inventory cleared.
- **DSA Growth**: Discovery awards +16% QoQ, offsetting 17% trailing 12M decline.
- **Liquidity Strength**: $38M cash vs $21.4M prior quarter, compliant with covenant amendments.

**【CEO Opening Remarks】**
- Q1 2025 revenue: $119.9M (-11.5% YoY), driven by 15.1% RMS decline due to lower NHP pricing.
- Key initiatives: 
  - $27.5M equity proceeds to improve liquidity.
  - NHP pre-sales for 2025 to reduce volatility.
  - $5M investment in RMS site consolidation, targeting $4-5M annual savings by Q4 2026.
- Outlook: Expect YoY revenue and EBITDA growth in Q2-Q4 2025, with improved NHP margins.

**【CFO Financial Summary】**
- GAAP net loss: $27.6M (-143% YoY), driven by lower NHP margins.
- Adjusted EBITDA: $2.6M (2.2% of rev) vs $9.6M (7.1% of rev) YoY.
- DSA segment: $42.8M (-4.3% YoY), 5.9% operating margin.
- RMS segment: $9.4M (7.9% of rev) vs $16.9M (12.5% of rev) YoY.
- Cash: $38M (vs $21.4M prior quarter), debt: $396M.

**【Q&A Key Takeaways】**
1. **NHP Inventory**: All high-cost inventory cleared; Q2+ pricing stable at 30% YoY decline.
2. **Market Dynamics**: Cambodia export uncertainty could tighten global supply; Inotiv diversified suppliers.
3. **Colony Management**: 20%+ growth expected, using 250/700 acres in Texas.
4. **DSA Trends**: Discovery service awards +16% QoQ, but trailing 12M down 17%.
5. **Liquidity**: Equity proceeds and reduced restructuring costs improve cash flow compliance with covenants.


Inotiv, Inc. (NOTV) Q1 2025 Earnings Call Transcript

Inotiv (NOTV)-3 Dec 24-2024 Q4 Earnings call transcript

Inotiv (NOTV)-8 Aug 24-2024 Q3 Earnings call transcript

Inotiv, Inc. (NOTV) Q2 2024 Earnings Call Transcript

Inotiv (NOTV)-7 Feb 24-2024 Q1 Earnings call transcript

Inotiv (NOTV)-11 Dec 23-2023 Q4 Earnings call transcript

- **First Quarter Profitability**: Inotiv achieved $1.8 million net income in Q3 2023, marking its first profitable quarter.
- **NHP Supply Crisis**: 47.9% YoY decline in US NHP imports through June led to 40% volume reduction in RMS, though pricing offsets revenue impact.
- **Strategic Initiatives**: 9 site closures completed, $20 million RMS cost savings, and $20 million quarterly EBITDA target for 2024.
- **DSA Momentum**: DSA backlog up 4% YoY to $149.1 million, with 11% YoY revenue growth despite discovery service challenges.
- **Updated Guidance**: 2023 revenue $570 million (-$10 million prior), EBITDA $60 million (-$10 million prior), reflecting cautious outlook on biotech funding and NHP supply.

**【CEO Opening Remarks】**
- Inotiv achieved Q3 2023 revenue of $157.5 million, down 9% YoY, with DSA (Discovery & Safety Assessment) revenue declining 5% to $46.8 million and RMS (Research Models & Services) revenue down 10% to $110.7 million.
- The company reported its first quarterly profitability, with adjusted EBITDA of $30.5 million (19.4% of revenue) and net income of $1.8 million.
- Key strategic initiatives include completing 9 of 11 planned site closures, reducing RMS expenses by $20 million, and targeting $20 million quarterly EBITDA in 2024.
- NHP (Non-Human Primate) imports from Cambodia dropped 47.9% YoY through June, leading to reduced RMS volumes but maintained pricing.
- DSA backlog grew to $149.1 million, up 4% YoY, with a book-to-bill ratio of 1.08x in Q3.

**【CFO Financial Overview】**
- Year-to-date 2023 revenue: $431.7 million (+9% YoY), with DSA up 11% and RMS up 8%.
- Q3 2023 gross profit: $55.2 million (35% of revenue), up 8.6% YoY, driven by RMS margin expansion to 34.2%.
- Operating income: $8.8 million (+83% YoY), with G&A expenses down $2.5 million QoQ to $26.6 million.
- Updated 2023 guidance: Revenue $570 million (-$10 million prior) and adjusted EBITDA $60 million (-$10 million prior), reflecting NHP supply constraints.
- Capital expenditures: $21.3 million (5% of revenue) for DSA capacity expansions and animal welfare improvements.

**【Q&A Highlights】**
- **NHP Supply Chain**: CEO Bob Leasure stated Q3 NHP volumes were 40% lower than Q3 2022, with no improvement expected in 2024. Pricing increases offset volume declines, but RMS revenue may remain flat.
- **DSA Growth**: CFO Beth Taylor expects DSA margins to expand to 30-35% in 2024 as new services (e.g., genetic toxicology) ramp up. Q3 bookings were record-high, but cancellations remain elevated.
- **Legal Expenses**: Q3 G&A included $4.1 million in legal fees for NHP-related matters, with potential ongoing costs.
- **2024 Outlook**: Target $20 million quarterly EBITDA, driven by DSA growth and RMS cost reductions. Management emphasized focus on AI-driven data integration to enhance translational medicine capabilities.

Inotiv (NOTV)-10 Aug 23-2023 Q3 Earnings call transcript

- **Revenue Growth**: 8% YoY to $151.5M, driven by 20.2% DSA expansion and RMS pricing improvements.
- **DSA Expansion**: Rockville and Fort Collins facilities nearing completion; targeting 50% revenue growth and 30-35% margins.
- **RMS Optimization**: $20M annual cost savings expected; Q2 NHP volumes down but prices up 3.3%.
- **Legal Headwinds**: $6.7M Q2 legal fees (Cambodia NHP, regulatory matters) cut adjusted EBITDA guidance to $70M.
- **Cash Flow**: $5.4M Q2 cash from ops; $24.6M cash on hand with debt covenant compliance.
- **NHP Strategy**: Testing protocols in development; no Cambodia imports since Nov 2022, but adequate inventory for DSA.

**【CEO Summary Section】**
- Total revenue increased 8% YoY to $151.5 million, driven by 20.2% growth in DSA segment ($47 million) and 3.3% growth in RMS segment ($104.5 million).
- DSA expansion in Rockville, MD and Fort Collins, CO is nearing completion, with genetic toxicology services contributing to revenue growth.
- RMS segment implemented favorable pricing for NHPs and Teklad diet, offsetting lower NHP volumes.
- Adjusted EBITDA improved to $17.1 million (11.3% of revenue), down from $25.3 million YoY due to $6.7 million in legal fees.
- Guidance updated to $70 million adjusted EBITDA (down from $75 million) due to legal expenses, with $580 million+ revenue target maintained.
- Long-term DSA goals include 50% revenue growth and 30-35% gross margins, with $20 million annualized cost savings from site optimizations.

**【CFO Financial Commentary】**
- DSA gross profit rose 32.1% of segment revenue (vs. 31.5% YoY), driven by higher sales and service expansion.
- RMS gross margin declined to 28.5% due to product mix, inflation, and duplicative costs from site closures.
- G&A expenses increased 36% YoY to $29 million, primarily from legal fees ($6.7 million) related to NHP and regulatory matters.
- Operating loss of $2.1 million reflected higher expenses and amortization, while net loss was $10 million (-$0.39 EPS).
- CapEx of $8.5 million (5.6% of revenue) focused on DSA capacity and animal welfare improvements.
- Cash flow from operations improved to $5.4 million, with $24.6 million in cash and compliance with debt covenants.

**【Q&A Highlights】**
- **NHP Strategy**: Cambodia imports paused since Nov 2022; testing protocols being developed for future verification. Adequate NHP inventory to meet DSA demand.
- **Business Environment**: Cautious pharma spending, but DSA bookings up 20% QoQ due to new services (e.g., genetic toxicology). Book-to-bill ratio 0.95x.
- **Staffing**: No significant headcount additions expected; 850 hires completed in FY2022 to support growth.
- **RMS Pricing**: Small animal prices held, NHP pricing increased Q2-Q3. RMS volume declines offset by price hikes.
- **Free Cash Flow**: Expecting cash generation in H2 as site optimizations complete, with $20 million annualized cost savings.
- **Legal Expenses**: Q2 legal fees ($6.7 million) expected to decline in Q3, with $9 million year-to-date total.


Inotiv (NOTV)-11 May 23-2023 Q2 Earnings call transcript

Inotiv (NOTV)-13 Feb 23-2023 Q1 Earnings call transcript

- **Revenue Growth**: FY22 revenue up 547% to $547.7 million, driven by RMS expansion and DSA organic growth.
- **EBITDA Guidance**: FY23 targets $75 million EBITDA, with Q2-Q4 margins at 17%.
- **NHP Supply Risk**: Imports from Cambodia paused; price hikes of 65%-100% to mitigate supply constraints.
- **Strategic Shifts**: Reduced M&A focus, $25 million FY23 CapEx for DSA expansion and RMS site closures.
- **Challenges**: Q1 2023 operating loss due to NHP shipment delays and higher cancellations.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2022 revenue rose fivefold to $150.5 million, with full-year revenue reaching $547.7 million, driven by RMS segment expansion and DSA organic growth of 31%.
- **EBITDA Performance**: Adjusted EBITDA for Q4 was $18.3 million (12.1% of revenue), up from $4.3 million in Q4 2021. Full-year EBITDA grew to $90.5 million (16.5% of revenue).
- **Challenges**: Higher operating costs ($271 million) due to recruitment, facility consolidations, and M&A-related expenses. NHP supply disruption led to delayed imports from Cambodia.
- **2023 Guidance**: Revenue of $580 million (Q1: $118-122 million, Q2-Q4: $460 million) and EBITDA of $75 million, with Q1 margin negative and Q2-Q4 at 17%.
- **Strategic Moves**: Investing $36.3 million in 2022 for DSA capacity expansion (30% increase) and RMS site optimizations, including closures of nine facilities.

**【CFO Financial Commentary】**
- **Financial Results**: Q4 GAAP net loss of $244.2 million due to $236 million goodwill impairment charge. DSA gross profit was $13 million (29.4% of segment revenue), RMS gross profit $29.2 million (27.5% of segment revenue).
- **Cost Management**: Operating expenses included restructuring ($200,000), M&A due diligence, and deferred legal fees. Adjusted unallocated G&A was $14.5 million (9.6% of revenue).
- **Capital Expenditure**: FY22 CapEx of $36.2 million for facility upgrades and technology. FY23 CapEx expected at $25 million for DSA expansions and animal welfare projects.

**【Q&A Highlights】**
- **NHP Supply**: Imports from Cambodia paused for audits; price increases of 65%-100% to offset supply constraints. RMS revenue in Q1 2023 down due to reduced NHP shipments.
- **Cancellation Trends**: Higher project cancellations (molecule delays, funding issues) offset by increased quoting activity. DSA backlog at $147.2 million as of Q4 2022.
- **Margin Improvements**: Site optimizations and price increases expected to enhance margins. DSA efficiency gains from new services (e.g., Rockville expansion).
- **Debt Management**: $353.7 million debt as of Q4 2022, compliant with covenants. Focus on organic growth and margin expansion rather than acquisitions.

Actual											-0.16	-0.03	-0.06	-0.15	0.06	-3.93	-0.24	-0.15	-9.54	-3.41	-0.39	0.07	-0.38	-0.6	-1.86	-1	-0.73	-1.02	-0.44	-0.51	-0.25	-0.83
Forecast												-0.19	-0.03	-0.08	-0.15	-0.0433	-0.64	-0.02	-0.08	-1.0133	-0.3359	0.0328	-0.1677	-0.5467	-0.3844	-0.835	-0.975	-0.7718	-0.635	-0.3935	-0.46	-0.638
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+84.21%	-100.00%	-87.50%	+140.00%	-8976.21%	+62.50%	-650.00%	-11825.00%	-236.52%	-16.11%	+113.41%	-126.60%	-9.75%	-383.87%	-19.76%	+25.13%	-32.16%	+30.71%	-29.61%	+45.65%	-30.09%

NOTV(Delisted)

NOTV(Delisted)

Inotiv (NOTV) Earnings

NOTV Q1 2026 Earnings

EPS

Revenue

Earnings Call

You can ask Aime